PBRM1 loss is associated with increased sensitivity to MCL1 and CDK9 inhibition in clear cell renal cancer.
Journal Information
Full Title: Front Oncol
Abbreviation: Front Oncol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"Conflict of interest All authors are or were employees of Prelude Therapeutics, Inc at the time of research, and may own equity in the company."
Funding Disclosure
Evidence found in paper:
"The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025